Home Health Care Regeneron secures FDA approval

Regeneron secures FDA approval

The U.S. Food and Drug Administration (FDA) on Sept. 21 approved Eylea Injection, developed by Regeneron Pharmaceuticals Inc., for the treatment of macular edema following central retinal vein occlusion.

This content is for Westfair Online members only. Please to view this content. Become a member by Registering Here.